RGNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Regenxbio Inc (RGNX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows promising growth in revenue and gross margin, the financial performance still reflects significant losses. The technical indicators and options data do not suggest strong bullish momentum, and there are no recent positive news catalysts or significant insider or hedge fund activity to support immediate investment. Analyst ratings remain mixed, with lowered price targets and cautious optimism around upcoming catalysts. For a patient, long-term investor, it may be better to wait for clearer positive signals or material catalysts before investing.
The technical indicators are neutral. The MACD is slightly positive but contracting, RSI is neutral at 44.577, and moving averages are converging. The stock is trading near its pivot level of 9.173, with support at 8.78 and resistance at 9.566. There are no strong bullish or bearish signals currently.
The company's revenue grew by 43% YoY in Q4 2025, and gross margin increased to 80.46%. Analysts highlight potential catalysts in upcoming data readouts for RGX-202/DMD and ABBV-RGX-314/wAMD.
The FDA's Complete Response Letter for RGX-121 raises concerns about regulatory challenges. Analysts have lowered price targets, and the stock has a 60% chance of declining in the short term.
In Q4 2025, revenue increased by 43% YoY to $30.34M, net income loss improved by 31.19% YoY to -$67.15M, EPS improved by 28.71% YoY to -1.3, and gross margin increased by 14.58% YoY to 80.46%. Despite improvements, the company remains unprofitable.
Analysts maintain mixed ratings. Several firms lowered price targets recently, citing regulatory challenges and uncertainty. However, some analysts remain optimistic about upcoming catalysts, with price targets ranging from $12 to $50.
